Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 09-Apr-24 6:00 PM View:  | Teehan Brendan EVP, COO, Head of Commercial | Acadia Pharmaceuticals Inc. (ACAD) | 08-Apr-24 | Planned Option Sale | 2,568 | $17.87 | $45,890.20 | (6%) 41.36K to 38.8K | |
| 09-Apr-24 6:00 PM View: | Schneyer Mark C. EVP, Chief Financial Officer | Acadia Pharmaceuticals Inc. (ACAD) | 08-Apr-24 | Planned Option Sale | 2,716 | $17.87 | $48,534.90 | (9%) 31.46K to 28.74K | |
| 09-Apr-24 6:00 PM View: | Davis Stephen CEO Director | Acadia Pharmaceuticals Inc. (ACAD) | 08-Apr-24 | Planned Option Sale | 26,574 | $17.87 | $474,877.00 | (16%) 170.84K to 144.27K | |
| 09-Apr-24 6:00 PM View: | Kihara James Principal Accounting Officer | Acadia Pharmaceuticals Inc. (ACAD) | 08-Apr-24 | Planned Option Sale | 1,790 | $17.87 | $31,987.30 | (12%) 14.89K to 13.1K | |
| 09-Apr-24 6:00 PM View: | Kihara James Principal Accounting Officer | Acadia Pharmaceuticals Inc. (ACAD) | 07-Apr-24 | Option Exercise | 1,489 | -- | -- | 11% 13.4K to 14.89K | |
| 09-Apr-24 6:00 PM View: | Teehan Brendan EVP, COO, Head of Commercial | Acadia Pharmaceuticals Inc. (ACAD) | 05-Apr-24 | Option Exercise | 5,024 | -- | -- | 14% 36.34K to 41.36K | |
| 09-Apr-24 6:00 PM View: | Schneyer Mark C. EVP, Chief Financial Officer | Acadia Pharmaceuticals Inc. (ACAD) | 05-Apr-24 | Option Exercise | 5,275 | -- | -- | 20% 26.18K to 31.46K | |
| 09-Apr-24 6:00 PM View: | Davis Stephen CEO Director | Acadia Pharmaceuticals Inc. (ACAD) | 05-Apr-24 | Option Exercise | 51,999 | -- | -- | 44% 118.84K to 170.84K | |
| 09-Apr-24 6:00 PM View: | Kihara James Principal Accounting Officer | Acadia Pharmaceuticals Inc. (ACAD) | 05-Apr-24 | Option Exercise | 2,010 | -- | -- | 18% 11.39K to 13.4K | |
| 27-Mar-24 7:58 PM View: | Davis Stephen CEO Director | Acadia Pharmaceuticals Inc. (ACAD) | 27-Mar-24 | Sale (Planned) | 17,714 | $17.90 | $317,081.00 | (13%) 136.56K to 118.84K | |
| 27-Mar-24 8:00 PM View: | Teehan Brendan EVP, COO, Head of Commercial | Acadia Pharmaceuticals Inc. (ACAD) | 27-Mar-24 | Sale (Planned) | 5,140 | $17.90 | $92,006.00 | (12%) 41.48K to 36.34K | |
| 27-Mar-24 7:57 PM View: | Schneyer Mark C. EVP, Chief Financial Officer | Acadia Pharmaceuticals Inc. (ACAD) | 27-Mar-24 | Sale (Planned) | 5,434 | $17.90 | $97,268.60 | (17%) 31.62K to 26.18K | |
| 27-Mar-24 8:00 PM View: | Teehan Brendan EVP, COO, Head of Commercial | Acadia Pharmaceuticals Inc. (ACAD) | 25-Mar-24 | Grant | 10,048 | -- | -- | 32% 31.43K to 41.48K | |
| 27-Mar-24 7:57 PM View: | Schneyer Mark C. EVP, Chief Financial Officer | Acadia Pharmaceuticals Inc. (ACAD) | 25-Mar-24 | Grant | 10,550 | -- | -- | 50% 21.07K to 31.62K | |
| 27-Mar-24 7:58 PM View: | Davis Stephen CEO Director | Acadia Pharmaceuticals Inc. (ACAD) | 25-Mar-24 | Grant | 34,666 | -- | -- | 34% 101.89K to 136.56K | |
| 27-Feb-24 6:07 PM View: | Kihara James Principal Accounting Officer | Acadia Pharmaceuticals Inc. (ACAD) | 26-Feb-24 | Planned Option Sale | 474 | $24.67 | $11,693.60 | (4%) 11.87K to 11.39K | |
| 27-Feb-24 6:10 PM View: | Teehan Brendan EVP, COO, Head of Commercial | Acadia Pharmaceuticals Inc. (ACAD) | 26-Feb-24 | Planned Option Sale | 624 | $24.67 | $15,394.10 | (2%) 32.06K to 31.43K | |
| 27-Feb-24 6:13 PM View: | Schneyer Mark C. EVP, Chief Financial Officer | Acadia Pharmaceuticals Inc. (ACAD) | 26-Feb-24 | Planned Option Sale | 772 | $24.67 | $19,045.20 | (4%) 21.84K to 21.07K | |
| 27-Feb-24 6:02 PM View: | Davis Stephen CEO Director | Acadia Pharmaceuticals Inc. (ACAD) | 26-Feb-24 | Planned Option Sale | 5,577 | $24.67 | $137,585.00 | (5%) 107.47K to 101.89K | |
| 27-Feb-24 6:07 PM View: | Kihara James Principal Accounting Officer | Acadia Pharmaceuticals Inc. (ACAD) | 23-Feb-24 | Option Exercise | 840 | -- | -- | 8% 11.03K to 11.87K | |
| 27-Feb-24 6:10 PM View: | Teehan Brendan EVP, COO, Head of Commercial | Acadia Pharmaceuticals Inc. (ACAD) | 23-Feb-24 | Option Exercise | 1,107 | -- | -- | 4% 30.95K to 32.06K | |
| 27-Feb-24 6:13 PM View: | Schneyer Mark C. EVP, Chief Financial Officer | Acadia Pharmaceuticals Inc. (ACAD) | 23-Feb-24 | Option Exercise | 1,353 | -- | -- | 7% 20.49K to 21.84K | |
| 27-Feb-24 6:02 PM View: | Davis Stephen CEO Director | Acadia Pharmaceuticals Inc. (ACAD) | 23-Feb-24 | Option Exercise | 10,946 | -- | -- | 11% 96.52K to 107.47K | |
| 09-Jan-24 6:00 PM View: | Teehan Brendan EVP, COO, Head of Commercial | Acadia Pharmaceuticals Inc. (ACAD) | 08-Jan-24 | Option Sale | 731 | $29.96 | $21,900.80 | (2%) 31.68K to 30.95K | |
| 09-Jan-24 6:00 PM View: | Davis Stephen CEO Director | Acadia Pharmaceuticals Inc. (ACAD) | 08-Jan-24 | Option Sale | 3,732 | $29.96 | $111,811.00 | (4%) 100.25K to 96.52K | |
| 09-Jan-24 6:00 PM View: | Kim Austin D. EVP,General Counsel, Secretary | Acadia Pharmaceuticals Inc. (ACAD) | 08-Jan-24 | Option Sale | 590 | $29.96 | $17,676.40 | (1%) 47.49K to 46.9K | |
| 09-Jan-24 6:00 PM View: | Kim Austin D. EVP,General Counsel, Secretary | Acadia Pharmaceuticals Inc. (ACAD) | 06-Jan-24 | Option Exercise | 1,634 | -- | -- | 4% 45.86K to 47.49K | |
| 09-Jan-24 6:00 PM View: | Teehan Brendan EVP, COO, Head of Commercial | Acadia Pharmaceuticals Inc. (ACAD) | 06-Jan-24 | Option Exercise | 1,287 | -- | -- | 4% 30.39K to 31.68K | |
| 09-Jan-24 6:00 PM View: | Davis Stephen CEO Director | Acadia Pharmaceuticals Inc. (ACAD) | 06-Jan-24 | Option Exercise | 9,528 | -- | -- | 11% 90.72K to 100.25K | |
| 15-Dec-23 7:37 PM View: | Kihara James Principal Accounting Officer | Acadia Pharmaceuticals Inc. (ACAD) | 15-Dec-23 | Private Sale (Planned) | 2,000 | $28.30 | $56,600.00 | (15%) 13.03K to 11.03K | |
| 28-Nov-23 5:32 PM View: | Garofalo Elizabeth A. Director | Acadia Pharmaceuticals Inc. (ACAD) | 24-Nov-23 | Gift | 2,918 | -- | -- | (16%) 18.78K to 15.86K | |
| 21-Nov-23 6:00 PM View: | Schneyer Mark C. EVP, Chief Financial Officer | Acadia Pharmaceuticals Inc. (ACAD) | 20-Nov-23 | Option Sale | 5,108 | $22.64 | $115,645.00 | (20%) 25.59K to 20.49K | |
| 21-Nov-23 6:00 PM View: | Kihara James Principal Accounting Officer | Acadia Pharmaceuticals Inc. (ACAD) | 20-Nov-23 | Option Sale | 1,985 | $22.64 | $44,940.40 | (13%) 15.01K to 13.03K | |
| 21-Nov-23 6:00 PM View: | Teehan Brendan EVP, COO, Head of Commercial | Acadia Pharmaceuticals Inc. (ACAD) | 20-Nov-23 | Option Sale | 4,960 | $22.64 | $112,294.00 | (14%) 35.35K to 30.39K | |
| 21-Nov-23 6:00 PM View: | Teehan Brendan EVP, COO, Head of Commercial | Acadia Pharmaceuticals Inc. (ACAD) | 17-Nov-23 | Option Exercise | 9,912 | -- | -- | 39% 25.44K to 35.35K | |
| 21-Nov-23 6:00 PM View: | Kihara James Principal Accounting Officer | Acadia Pharmaceuticals Inc. (ACAD) | 17-Nov-23 | Option Exercise | 3,964 | -- | -- | 36% 11.05K to 15.01K | |
| 21-Nov-23 6:00 PM View: | Schneyer Mark C. EVP, Chief Financial Officer | Acadia Pharmaceuticals Inc. (ACAD) | 17-Nov-23 | Option Exercise | 9,912 | -- | -- | 63% 15.68K to 25.59K | |
| 16-Oct-23 5:30 PM View: | Ndu Adora Director | Acadia Pharmaceuticals Inc. (ACAD) | 12-Oct-23 | Option Exercise | 4,381 | -- | -- | 100% 0 to 4.38K | |
| 06-Oct-23 10:00 PM View: | Kim Austin D. EVP,General Counsel, Secretary | Acadia Pharmaceuticals Inc. (ACAD) | 06-Oct-23 | Option Sale | 16,369 | $21.96 | $359,463.00 | (26%) 62.23K to 45.86K | |
| 06-Oct-23 9:59 PM View: | Davis Stephen CEO Director | Acadia Pharmaceuticals Inc. (ACAD) | 06-Oct-23 | Option Sale | 51,563 | $21.96 | $1,132,320.00 | (37%) 140.69K to 89.13K | |
| 06-Oct-23 10:00 PM View: | Kim Austin D. EVP,General Counsel, Secretary | Acadia Pharmaceuticals Inc. (ACAD) | 05-Oct-23 | Option Exercise | 36,174 | -- | -- | 139% 26.05K to 62.23K | |
| 06-Oct-23 9:59 PM View: | Davis Stephen CEO Director | Acadia Pharmaceuticals Inc. (ACAD) | 05-Oct-23 | Option Exercise | 103,999 | -- | -- | 283% 36.7K to 140.69K | |
| 19-Sep-23 6:31 PM View: | Kihara James Principal Accounting Officer | Acadia Pharmaceuticals Inc. (ACAD) | 15-Sep-23 | Private Sale (Planned) | 2,000 | $25.88 | $51,760.00 | (16%) 12.78K to 10.78K | |
| 23-Aug-23 7:31 PM View: | Schneyer Mark C. EVP, Chief Financial Officer | Acadia Pharmaceuticals Inc. (ACAD) | 21-Aug-23 | Private Sale (Planned) | 10,000 | $29.00 | $289,970.00 | (39%) 25.68K to 15.68K | |
| 18-Jul-23 6:00 PM View: | Davis Stephen CEO Director | Acadia Pharmaceuticals Inc. (ACAD) | 14-Jul-23 | Planned Private Option Sale | 100,000 | $30.04 | $3,004,350.00 | (73%) 136.69K to 36.7K | |
| 18-Jul-23 6:00 PM View: | Davis Stephen CEO Director | Acadia Pharmaceuticals Inc. (ACAD) | 14-Jul-23 | Option Exercise | 100,000 | $20.77 | $2,077,000.00 | 273% 36.7K to 136.69K | 9% |
| 13-Jul-23 8:27 PM View: | Davis Stephen CEO Director | Acadia Pharmaceuticals Inc. (ACAD) | 12-Jul-23 | Sale (Planned) | 55,104 | $25.05 | $1,380,450.00 | (60%) 91.8K to 36.7K | |
| 13-Jul-23 8:27 PM View: | Davis Stephen CEO Director | Acadia Pharmaceuticals Inc. (ACAD) | 11-Jul-23 | Private Sale (Planned) | 16,498 | $25.00 | $412,450.00 | (15%) 108.3K to 91.8K | |
| 14-Jun-23 5:14 PM View: | Brege Laura Director | Acadia Pharmaceuticals Inc. (ACAD) | 12-Jun-23 | Private Sale (Planned) | 4,500 | $24.87 | $111,906.00 | (25%) 18.0K to 13.5K | |
| 12-Jun-23 8:48 PM View: | Schneyer Mark C. EVP, Chief Financial Officer | Acadia Pharmaceuticals Inc. (ACAD) | 08-Jun-23 | Option Sale | 974 | $25.02 | $24,369.50 | (4%) 23.8K to 22.82K |
